Hantz Financial Services Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hantz Financial Services Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 87.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 73 shares of the biopharmaceutical company’s stock after purchasing an additional 34 shares during the period. Hantz Financial Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $77,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of REGN. International Assets Investment Management LLC lifted its holdings in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Regeneron Pharmaceuticals by 23.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares during the period. TD Asset Management Inc grew its stake in Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after buying an additional 82,034 shares in the last quarter. Icon Wealth Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Regeneron Pharmaceuticals by 86.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 144,865 shares of the biopharmaceutical company’s stock worth $152,257,000 after acquiring an additional 67,235 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Citigroup initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price target for the company. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Trading Up 1.6 %

REGN opened at $762.34 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a 50 day simple moving average of $905.64 and a two-hundred day simple moving average of $1,019.64. The firm has a market capitalization of $83.77 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 2.89 and a beta of 0.15.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.